

Atty. Docket No.: PR60153US

REMARKS

Claims 1- 60 are pending in this application. The Examiner has required restriction to one of 3 groups: Group I, claims 1-18, 23, 30-32, 36-53 and 57-58 drawn to pharmaceutical compositions; Group II, claims 19-22, 27-29 and 54-56 drawn to methods of making pharmaceutical compositions; and Group III, claims 24-26, 33-35 and 54-60 drawn to methods of using lithium carbonate pharmaceutical compositions for the treatment of bipolar disorder and manic depression. In response to such restriction Applicants wish to proceed as follows.

Applicants elect without traverse Group I, claims 1-18, 23, 30-32, 36-53 and 57-58, for proceeding with prosecution on the merits. The election is made without traverse in that it is believed that these claims are patentably distinct from the claims of Groups II and III.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Robert J. Smith
Attorney for Applicants
Registration No. 40,820

Date: 10-25-05
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
Telephone: (919) 483-9616
Facsimile: (919) 483-7988